John C Panetta
Overview
Explore the profile of John C Panetta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
104
Citations
2576
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yarur A, Dervieux T, Ungaro R, Spencer E, Bruss A, Nunez L, et al.
Pharmaceutics
. 2025 Feb;
17(2).
PMID: 40006554
: This study aimed to compare the association of ustekinumab (UST) drug clearance (CL) and trough drug concentrations with disease activity in patients with inflammatory bowel diseases (IBDs). : A...
2.
Panetta J, Ashcraft E, Jeha S, Pui C, Inaba H, Karol S, et al.
Haematologica
. 2025 Feb;
PMID: 39945009
Not available.
3.
Panetta J, Selvo N, Mater D, Stewart C
Pharmaceutics
. 2025 Jan;
16(12.
PMID: 39771507
Palbociclib, an oral CDK 4/6 inhibitor, was evaluated in a Pediatric Brain Tumor Consortium (PBTC) phase 1 (NCT02255461; PBTC-042) study to treat children and young adults with recurrent, progressive, or...
4.
Vermeire S, Dubinsky M, Rabizadeh S, Panetta J, Spencer E, Dreesen E, et al.
Clin Res Hepatol Gastroenterol
. 2024 May;
48(6):102374.
PMID: 38750934
Background: Infliximab (IFX) exposure is established as a predictive factor of pharmacokinetic (PK) origin in inflammatory bowel disease (IBD), and expert consensus is to achieve adequate exposure during induction to...
5.
Gaietto A, Panetta J, Pauley J, Relling M, Ribeiro R, Ehrhardt M, et al.
Cancer Chemother Pharmacol
. 2024 Feb;
93(6):617-625.
PMID: 38416167
Purpose: The intraventricular route of chemotherapy administration, via an Ommaya Reservoir (OmR) improves drug distribution in the central nervous system (CNS) compared to the more commonly used intrathecal administration. We...
6.
Dubinsky M, Rabizadeh S, Panetta J, Spencer E, Everts-van der Wind A, Dervieux T
Pharmaceutics
. 2023 Oct;
15(10).
PMID: 37896168
Infliximab (IFX) concentrations are a predictive factor (PF) of pharmacokinetic (PK) origin in the treatment of Crohn's disease (CD). We evaluated Clearance, another PF of PK origin, either alone or...
7.
Pai A, Mohanan E, Panetta J, Kulkarni U, Stallon Illangeswaran R, Balakrishnan B, et al.
Clin Pharmacol Ther
. 2023 Oct;
115(1):116-125.
PMID: 37846495
A toxicity-reduced conditioning regimen with treosulfan, fludarabine, and thiotepa in patients with high-risk β-thalassemia major has significantly improved hematopoietic stem cell transplantation (HCT) outcomes. However, complications resulting from regimen-related toxicities...
8.
Wright E, Chaparro M, Gionchetti P, Hamilton A, Schulberg J, Gisbert J, et al.
J Crohns Colitis
. 2023 Aug;
18(2):212-222.
PMID: 37594369
Objective: We postulated that adalimumab [ADA] drug clearance [CL] may be a more critical determinant of therapeutic outcome than ADA concentration. This was tested in Crohn's disease [CD] patients undergoing...
9.
Purvis K, Swanson H, Niloy K, Zhou Y, Panetta J, Crews K, et al.
Cancer Chemother Pharmacol
. 2023 May;
92(1):1-6.
PMID: 37199744
Purpose: The Stanford V chemotherapy regimen has been used to treat Hodgkin lymphoma (HL) patients since 2002 with excellent cure rates; however, mechlorethamine is no longer available. Bendamustine, a drug...
10.
Yoshimura S, Panetta J, Hu J, Li L, Gocho Y, Du G, et al.
Leukemia
. 2023 Apr;
37(6):1194-1203.
PMID: 37076694
LCK is a novel therapeutic target in ~40% of T-cell acute lymphoblastic leukemia (T-ALL), and dasatinib and ponatinib can act as LCK inhibitors with therapeutic effects. We herein report a...